Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • Log out
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • Log out
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

Mutations in fusA Associated with Posttherapy Fusidic Acid Resistance in Clostridium difficile

T. Norén, T. Åkerlund, M. Wullt, L. G. Burman, M. Unemo
T. Norén
Department of Infectious Diseases
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: torbjorn.noren@orebroll.se
T. Åkerlund
Swedish Institute for Infectious Disease Control, Solna, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Wullt
Örebro University Hospital, Örebro, Department of Clinical Sciences, Malmö, Lund University, Lund
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. G. Burman
Swedish Institute for Infectious Disease Control, Solna, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Unemo
Department of Clinical Microbiology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01283-06
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

In silico, we identified fusA (2,067 bp) in Clostridium difficile 630. Sequencing of fusA in posttherapy fusidic acid-resistant C. difficile isolates from 12 patients with C. difficile-associated diarrhea (CDAD) identified fusA mutations, one or two nonsynonymous substitutions, or in one case a deletion of one codon associated with resistance. Five of these mutations have previously been described in fusA of fusidic acid-resistant Staphylococcus aureus, but seven were novel fusA mutations. Fusidic acid monotherapy for CDAD seemed to rapidly select conserved resistant mutants.

Fusidic acid, derived from Fusidium coccineum (7), is used for the treatment of staphylococcal bone and soft tissue infections; and resistance in Staphylococcus aureus is mainly due to mutations in fusA (2, 14). This gene encodes a ribosomal translocation enzyme, elongation factor G (EF-G), which is crucial to bacterial protein synthesis and which represents the target of fusidic acid (10). fusA has also been described in, e.g., Bacillus subtilis (9), Bacillus cereus (23), Clostridium acetobutylicum (15), Clostridium perfringens (25), Clostridium tetani (3), and Salmonella enterica serovar Typhimurium (8, 12).

A decline in the rate of cure of C. difficile-associated diarrhea (CDAD) with metronidazole (6, 13) opened the way for fusidic acid as an alternative treatment, found to have a clinical efficacy similar to that of metronidazole (5, 27, 29). The in vitro susceptibility of C. difficile to fusidic acid is generally excellent (4, 11), and like for metronidazole, the high fusidic acid absorption (98%) (24) presumably results in sufficient therapeutic concentrations in feces from an inflammatory mucosa. However, we recently found that 55% of the fusidic acid-treated CDAD patients with posttherapy persistent C. difficile carried fusidic acid-resistant isolates of identical PCR ribotypes at follow-up (16). Our aims were to identify fusA of C. difficile, to explore the heterogeneity of the gene, and to find mutations associated with the emergence of fusidic acid resistance.

Origin, culture, MIC determination, and PCR ribotyping of C. difficile isolates.

Of 44 patients treated with fusidic acid in our previous study (16), 20 (45%) had C. difficile persisting at follow-up, and 11 (55%) of these patients carried fusidic acid-resistant C. difficile isolates (n = 12) (Table 1). These isolates were selected for study, together with the resistant isolates recovered both pre- and posttherapy from one patient randomized to metronidazole (Table 1, patient 12) but who had received fusidic acid 2 weeks before inclusion in the study. Thus, the putative fusA genes of 27 paired C. difficile isolates from 12 patients were sequenced. Culture, MIC determination, and PCR ribotyping of the isolates were performed as described previously (16, 17).

View this table:
  • View inline
  • View popup
TABLE 1.

Mutations in fusA associated with posttherapy fusidic acid-resistant Clostridium difficilea

DNA isolation and PCR of putative fusA.

C. difficile isolates cultured anaerobically in peptone yeast medium for 24 h were pelleted, dissolved in 5% Chelex 100 resin (Bio-Rad Laboratories, Hercules, CA), and boiled for 10 min. After centrifugation, the supernatant was used for PCR. The first segment (approximately 1.2 kbp) of fusA and the remaining segment of the gene (approximately 0.9 kbp), identified as described below, were amplified separately by using a LightCycler real-time PCR system (Roche Molecular Biochemicals, Mannheim, Germany) and the primers described in Table 2.

View this table:
  • View inline
  • View popup
TABLE 2.

Primers used for PCR amplification and sequencing of fusA alleles

Sequencing, alignments, and phylogenetic analysis.

The amplicons of fusA were purified by using a High Pure PCR product purification kit (Roche) and were sequenced with the primers described in Table 2 by using the BigDye Terminator (version 3.1) cycle sequencing kit (Applied Biosystems, Foster City, CA) and an ABI Prism 3100 genetic analyzer (Applied Biosystems). Alignments of entire fusA sequences, encoding mature EF-G, and the deduced amino acid sequences were performed with BioEdit (version 5.0.9) software. Phylogenetic analysis was performed with TREECON (version 1.3b) software, as described previously (26).

Identification of fusA in C. difficile.

A BLAST search of the genome of C. difficile strain 630 (http://www.sanger.ac.uk/Projects/C_difficile/) by using fusA of C. perfringens (GenBank accession no. NC_003366) identified a putative fusA (2,067 bp) in the C. difficile genome (nucleotide positions 98757 to 100823) comprising an open reading frame encoding 688 amino acids. This gene displayed 72%, 70%, and 67% identities to fusA of C. perfringens, C. acetobutylicum, and B. subtilis, respectively. By using the putative fusA of C. difficile strain 630, primers for PCR and sequencing of the gene were constructed.

Comparison of fusA sequences.

Among the 27 C. difficile isolates studied, 18 unique fusA alleles and a total of 44 polymorphic nucleotide sites (2.1 per 100 sites) were identified. These comprised synonymous substitutions (n = 26), nonsynonymous substitutions (n = 15), and one 3-bp deletion (i.e., a codon). Alignment of the deduced EF-G amino acid sequences showed 13 polymorphic sites (1.9 per 100 sites).

The wild-type fusA sequences, i.e., those present in the fusidic acid-susceptible C. difficile isolates obtained on day 1, comprised 26 synonymous substitutions and 4 nonsynonymous substitutions.

However, each fusidic acid-resistant isolate had a fusA sequence identical to that of its corresponding susceptible day 1 isolate, except for one or two nonsynonymous substitutions or in one case a deletion of one codon (Table 1). A total of 10 distinct EF-G sequence variants were identified among all the 14 resistant isolates. Whereas the deletion of one amino acid (A375) resulted in a moderately increased MIC (4 mg/liter), the amino acid alterations in EF-G yielded MICs of 64 mg/liter (1 isolate) and >256 mg/liter (12 isolates).

Growth characteristics, morphology, and stability of resistant mutants.

Neither colony numbers nor colony morphologies differed between the fusidic acid-susceptible isolate and the corresponding resistant mutant after subcultivation of the 27 isolates 10-fold over 22 days (data not shown). The fusidic acid MICs measured initially and after the last subcultivation were identical for 20 isolates and differed by a maximum of ±1 log2 (mg/liter) in 7 isolates.

We identified fusA in C. difficile and found that one or two nonsynonymous mutations in fusA represented the genetic key to fusidic acid resistance in C. difficile.

Five of the resistance-associated mutations identified, i.e., A374→V, D432→N, T434→I, H455→N, and H455→Q, have been described at corresponding positions of the S. aureus fusA (1, 14, 18, 19). The remaining ones (n = 7) were novel mutations associated with fusidic acid resistance and comprised either a variant substitution at a classical position (1, 18, 19), i.e., the S449→P, H455→R, and I459→R substitutions, or mutations not previously identified in any species, i.e., the M16→I, S116→L, and V119→A mutations and the deletion of A375 (Table 1). The fusidic acid resistance-associated mutations in C. difficile were mainly located in clusters, and as described for S. aureus (18), distinct locations in FusA appeared to be especially important for resistance, such as amino acid residues 432 to 459 (Table 1). This region also comprises the amino acids, centered on H455, that presumably interact directly with the fusidic acid molecule (10). In contrast to the variable levels of fusidic acid resistance associated with fusA mutations in S. aureus, all but one (deletion of A375) conferred high-level resistance. Nevertheless, additional mechanisms of fusidic acid resistance may exist in C. difficile, as reported for S. aureus (14, 18, 22). Interestingly, the in vitro growth characteristics did not differ between the resistant and the susceptible isolates, and no reversion of resistance was seen in subcultured mutant isolates. This finding, together with the late isolation of resistant C. difficile on days 35 to 40 in the absence of antimicrobial therapy, supported the notion of the frequent selection of stable fusidic acid-resistant mutants, as previously found for, e.g., S. aureus (20, 21, 28). Primary fusidic acid resistance in C. difficile is seldom seen (4, 11). However, this is probably due to the limited use of this antimicrobial in clinical practice.

ACKNOWLEDGMENTS

We thank Ingegerd Alriksson and Ingela Persson for technical assistance and Inga Odenholt and Erik Bäck for continuous support.

The present study was supported by grants from the Research Committee of Örebro County.

FOOTNOTES

    • Received 13 October 2006.
    • Returned for modification 10 November 2006.
    • Accepted 2 February 2007.
  • ↵▿ Published ahead of print on 16 February 2007.

  • American Society for Microbiology

REFERENCES

  1. ↵
    Besier, S., A. Ludwig, V. Brade, and T. A. Wichelhaus. 2003. Molecular analysis of fusidic acid resistance in Staphylococcus aureus. Mol. Microbiol. 47:463-469.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    Brown, E. M., and P. Thomas. 2002. Fusidic acid resistance in Staphylococcus aureus isolates. Lancet 359:803.
    OpenUrlPubMedWeb of Science
  3. ↵
    Bruggemann, H., S. Baumer, W. F. Fricke, A. Wiezer, H. Liesegang, I. Decker, C. Herzberg, R. Martinez-Arias, R. Merkl, A. Henne, and G. Gottschalk. 2003. The genome sequence of Clostridium tetani, the causative agent of tetanus disease. Proc. Natl. Acad. Sci. USA 100:1316-1321.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Burdon, D. W., J. D. Brown, D. J. Youngs, Y. Arabi, N. Shinagawa, J. Alexander-Williams, M. R. Keighley, and R. H. George. 1979. Antibiotic susceptibility of Clostridium difficile. J. Antimicrob. Chemother. 5:307-310.
    OpenUrlCrossRefPubMed
  5. ↵
    Cronberg, S., B. Castor, and A. Thoren. 1984. Fusidic acid for the treatment of antibiotic-associated colitis induced by Clostridium difficile. Infection 12:276-279.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Fernandez, A., G. Anand, and F. Friedenberg. 2004. Factors associated with failure of metronidazole in Clostridium difficile-associated disease. J. Clin. Gastroenterol. 38:414-418.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    Godtfredsen, W., K. Roholt, and L. Tybring. 1962. Fucidin: a new orally active antibiotic. Lancet i:928-931.
  8. ↵
    Johanson, U., and D. Hughes. 1994. Fusidic acid-resistant mutants define three regions in elongation factor G of Salmonella typhimurium. Gene 143:55-59.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    Kunst, F., N. Ogasawara, I. Moszer, A. M. Albertini, G. Alloni, V. Azevedo, M. G. Bertero, P. Bessieres, A. Bolotin, S. Borchert, R. Borriss, L. Boursier, A. Brans, M. Braun, S. C. Brignell, S. Bron, S. Brouillet, C. V. Bruschi, B. Caldwell, V. Capuano, N. M. Carter, S. K. Choi, J. J. Codani, I. F. Connerton, A. Danchin, et al. 1997. The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature 390:249-256.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    Laurberg, M., O. Kristensen, K. Martemyanov, A. T. Gudkov, I. Nagaev, D. Hughes, and A. Liljas. 2000. Structure of a mutant EF-G reveals domain III and possibly the fusidic acid binding site. J. Mol. Biol. 303:593-603.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    Leroi, M. J., S. Siarakas, and T. Gottlieb. 2002. E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid. Eur. J. Clin. Microbiol. Infect. Dis. 21:72-74.
    OpenUrlCrossRefPubMed
  12. ↵
    Macvanin, M., J. Bjorkman, S. Eriksson, M. Rhen, D. I. Andersson, and D. Hughes. 2003. Fusidic acid-resistant mutants of Salmonella enterica serovar Typhimurium with low fitness in vivo are defective in RpoS induction. Antimicrob. Agents Chemother. 47:3743-3749.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Musher, D. M., S. Aslam, N. Logan, S. Nallacheru, I. Bhaila, F. Borchert, and R. J. Hamill. 2005. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin. Infect. Dis. 40:1586-1590.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    Nagaev, I., J. Bjorkman, D. I. Andersson, and D. Hughes. 2001. Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol. Microbiol. 40:433-439.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    Nolling, J., G. Breton, M. V. Omelchenko, K. S. Makarova, Q. Zeng, R. Gibson, H. M. Lee, J. Dubois, D. Qiu, J. Hitti, Y. I. Wolf, R. L. Tatusov, F. Sabathe, L. Doucette-Stamm, P. Soucaille, M. J. Daly, G. N. Bennett, E. V. Koonin, and D. R. Smith. 2001. Genome sequence and comparative analysis of the solvent-producing bacterium Clostridium acetobutylicum. J. Bacteriol. 183:4823-4838.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Norén, T., M. Wullt, T. Åkerlund, E. Bäck, I. Odenholt, and L. G. Burman. 2006. Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid. Antimicrob. Agents Chemother. 50:3028-3032.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Norén, T., T. Åkerlund, E. Bäck, L. Sjöberg, I. Persson, I. Alriksson, and L. G. Burman. 2004. Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county. J. Clin. Microbiol. 42:3635-3643.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    O'Neill, A. J., J. M. Bostock, A. M. Moita, and I. Chopra. 2002. Antimicrobial activity and mechanisms of resistance to cephalosporin P1, an antibiotic related to fusidic acid. J. Antimicrob. Chemother. 50:839-848.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    O'Neill, A. J., A. R. Larsen, A. S. Henriksen, and I. Chopra. 2004. A fusidic acid-resistant epidemic strain of Staphylococcus aureus carries the fusB determinant, whereas fusA mutations are prevalent in other resistant isolates. Antimicrob. Agents Chemother. 48:3594-3597.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Österlund, A., T. Eden, B. Olsson-Liljequist, S. Haeggman, and G. Kahlmeter. 2002. Clonal spread among Swedish children of a Staphylococcus aureus strain resistant to fusidic acid. Scand. J. Infect. Dis. 34:729-734.
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    Peeters, K. A., E. M. Mascini, and C. J. Sanders. 2004. Resistance of Staphylococcus aureus to fusidic acid. Int. J. Dermatol. 43:235-236.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    Projan, S. J. 2000. Antibiotic resistance in the staphylococci. In U. A. Fischetti, R. P. Norvich, J. J. Ferretti, D. A. Portnoy, and J. I. Rood (ed.), Gram-positive pathogens. American Society for Microbiology, Washington, DC.
  23. ↵
    Rasko, D. A., J. Ravel, O. A. Okstad, E. Helgason, R. Z. Cer, L. Jiang, K. A. Shores, D. E. Fouts, N. J. Tourasse, S. V. Angiuoli, J. Kolonay, W. C. Nelson, A. B. Kolsto, C. M. Fraser, and T. D. Read. 2004. The genome sequence of Bacillus cereus ATCC 10987 reveals metabolic adaptations and a large plasmid related to Bacillus anthracis pXO1. Nucleic Acids Res. 32:977-988.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    Reeves, D. S. 1987. The pharmacokinetics of fusidic acid. J. Antimicrob. Chemother. 20:467-476.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    Shimizu, T., K. Ohtani, H. Hirakawa, K. Ohshima, A. Yamashita, T. Shiba, N. Ogasawara, M. Hattori, S. Kuhara, and H. Hayashi. 2002. Complete genome sequence of Clostridium perfringens, an anaerobic flesh-eater. Proc. Natl. Acad. Sci. USA 99:996-1001.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Unemo, M., P. Olcen, J. Albert, and H. Fredlund. 2003. Comparison of serologic and genetic porB-based typing of Neisseria gonorrhoeae: consequences for future characterization. J. Clin. Microbiol. 41:4141-4147.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Wenisch, C., B. Parschalk, M. Hasenhundl, A. M. Hirschl, and W. Graninger. 1996. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin. Infect. Dis. 22:813-818.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    Weston, V. C., T. C. Boswell, R. G. Finch, and W. Perkins. 2002. Fusidic acid cream for impetigo. Emergence of resistance to fusidic acid limits its use. BMJ 324:1394.
    OpenUrlCrossRefPubMed
  29. ↵
    Wullt, M., and I. Odenholt. 2004. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J. Antimicrob. Chemother. 54:211-216.
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Mutations in fusA Associated with Posttherapy Fusidic Acid Resistance in Clostridium difficile
T. Norén, T. Åkerlund, M. Wullt, L. G. Burman, M. Unemo
Antimicrobial Agents and Chemotherapy Apr 2007, 51 (5) 1840-1843; DOI: 10.1128/AAC.01283-06

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Mutations in fusA Associated with Posttherapy Fusidic Acid Resistance in Clostridium difficile
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
Share
Mutations in fusA Associated with Posttherapy Fusidic Acid Resistance in Clostridium difficile
T. Norén, T. Åkerlund, M. Wullt, L. G. Burman, M. Unemo
Antimicrobial Agents and Chemotherapy Apr 2007, 51 (5) 1840-1843; DOI: 10.1128/AAC.01283-06
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • Origin, culture, MIC determination, and PCR ribotyping of C. difficile isolates.
    • DNA isolation and PCR of putative fusA.
    • Sequencing, alignments, and phylogenetic analysis.
    • Identification of fusA in C. difficile.
    • Comparison of fusA sequences.
    • Growth characteristics, morphology, and stability of resistant mutants.
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

Copyright © 2019 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596